Giorgia Guglielmi
Giorgia Guglielmi is a freelance science writer based in Basel, Switzerland. Specializing in life sciences, medicine, and the relationship between science and society, she has published numerous articles in outlets including Nature, Science, and Scientific American. She holds a PhD in biology from the European Molecular Biology Laboratory and a Master’s in Science Writing from the Massachusetts Institute of Technology. She has received recognition for her work, including the John Kendrew Award in 2020 and an ERC-funded FRONTIERS Media Fellowship in 2025. She has also led lectures and workshops on science communication at institutions such as Harvard University and the University of Zurich.
HMGB1 is a key protein that blocks bacterial adhesion and virulence, protecting intestinal cells and helping to maintain a healthy microbiota.
Modifying the microbiota through a fecal transplant can be safely combined with immunotherapy in people with kidney cancer.
Restoring R. gnavus or supplementing isovaleric acid could be a promising microbiota–based strategy to prevent or treat atrial fibrillation.
Azelaic acid travels from the gut to the lungs, where it activates immune cells to reduce inflammation and protect the lungs.
Even after long breaks, such as summer vacation, babies continued to share more microbes with former nursery peers than with children from other nurseries.
E. coli 541-15 helps the colon recruit key immune cells that can develop into macrophages.
Computer models combining oral bacteria, their metabolic functions, and saliva chemicals could better distinguish obese from healthy individuals compared with clinical measurements alone.
A youthful gut microbiota can improve the regenerative function of aged intestinal stem cells.
VOS, an FDA-approved oral microbiota therapy, has been shown to reduce infection risk compared to traditional fecal transplants.
Effective treatment of IBD requires an approach combining tailored donors, microbiota analysis, and diet.
